Veradermics (MANE) Equity Ratio (2024 - 2026)

Veradermics has reported Equity Ratio for 3 years, with the latest figure at 0.98 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio changed N/A year-over-year to 0.98; the trailing twelve-month figure through Mar 2026 stood at 0.98 (changed N/A YoY), and the FY2025 full-year result was 0.79, up 9.17% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.98, up from 0.79 in the prior quarter.
• The five-year high for Equity Ratio was 0.98 in Q1 2026, with the low at 0.87 in Q4 2024.
• Historically, Equity Ratio has averaged 0.23 across 3 years, with a median of 0.79 in 2025.
• The largest YoY upside for Equity Ratio was 9.17% in 2025 against a maximum downside of 9.17% in 2025.
• Veradermics' Equity Ratio stood at 0.87 in 2024, then grew by 9.17% to 0.79 in 2025, then surged by 223.99% to 0.98 in 2026.
• The last three Equity Ratio figures came in at 0.98 (Q1 2026), 0.79 (Q4 2025), and 0.87 (Q4 2024), per Business Quant data.